Prudential Financial’s Akebia Therapeutics AKBA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $56K | Sell |
40,274
-11,250
| -22% | -$15.5K | ﹤0.01% | 2300 |
|
|
2025
Q4 | $83K | Sell |
51,524
-229,034
| -82% | -$480K | ﹤0.01% | 2126 |
|
|
2025
Q3 | $766K | Sell |
280,558
-134,585
| -32% | -$448K | ﹤0.01% | 1758 |
|
|
2025
Q2 | $1.51M | Buy |
415,143
+350,504
| +542% | +$963K | ﹤0.01% | 1502 |
|
|
2025
Q1 | $124K | Buy |
64,639
+170
| +0.3% | +$347 | ﹤0.01% | 2109 |
|
|
2024
Q4 | $122K | Hold |
64,469
| – | – | ﹤0.01% | 2131 |
|
|
2024
Q3 | $85.1K | Buy |
64,469
+50,200
| +352% | +$67K | ﹤0.01% | 2594 |
|
|
2024
Q2 | $14.6K | Sell |
14,269
-23,840
| -63% | -$29.5K | ﹤0.01% | 2677 |
|
|
2024
Q1 | $69.7K | Buy |
38,109
+16,000
| +72% | +$25.6K | ﹤0.01% | 2562 |
|
|
2023
Q4 | $27.4K | Sell |
22,109
-25,400
| -53% | -$25.9K | ﹤0.01% | 2600 |
|
|
2023
Q3 | $54.2K | Hold |
47,509
| – | – | ﹤0.01% | 2494 |
|
|
2023
Q2 | $43.5K | Buy |
+47,509
| New | +$45.9K | ﹤0.01% | 2546 |
|
|
2022
Q2 | – | Sell |
-249,912
| Closed | -$177K | – | 2658 |
|
|
2022
Q1 | $177K | Sell |
249,912
-381,000
| -60% | -$815K | ﹤0.01% | 2519 |
|
|
2021
Q4 | $1.43M | Sell |
630,912
-452,993
| -42% | -$1.24M | ﹤0.01% | 1707 |
|
|
2021
Q3 | $3.12M | Buy |
1,083,905
+1,062,864
| +5,051% | +$3.03M | ﹤0.01% | 1227 |
|
|
2021
Q2 | $80K | Buy |
21,041
+2,655
| +14% | +$8.94K | ﹤0.01% | 2503 |
|
|
2021
Q1 | $62K | Buy |
18,386
+60
| +0.3% | +$216 | ﹤0.01% | 2452 |
|
|
2020
Q4 | $51K | Hold |
18,326
| – | – | ﹤0.01% | 2409 |
|
|
2020
Q3 | $46K | Buy |
18,326
+6,659
| +57% | +$58.4K | ﹤0.01% | 2390 |
|
|
2020
Q2 | $158K | Buy |
+11,667
| New | +$121K | ﹤0.01% | 2294 |
|
|
2020
Q1 | – | Sell |
-12,760
| Closed | -$81K | – | 2347 |
|
|
2019
Q4 | $81K | Buy |
12,760
+1,600
| +14% | +$7.6K | ﹤0.01% | 2384 |
|
|
2019
Q3 | $44K | Buy |
11,160
+1,143
| +11% | +$4.9K | ﹤0.01% | 2384 |
|
|
2019
Q2 | $48K | Sell |
10,017
-12,540
| -56% | -$71.3K | ﹤0.01% | 2423 |
|
|
2019
Q1 | $185K | Sell |
22,557
-2,476
| -10% | -$17K | ﹤0.01% | 2328 |
|
|
2018
Q4 | $138K | Buy |
25,033
+6,673
| +36% | +$52.2K | ﹤0.01% | 2281 |
|
|
2018
Q3 | $162K | Sell |
18,360
-410
| -2% | -$3.67K | ﹤0.01% | 2355 |
|
|
2018
Q2 | $187K | Buy |
+18,770
| New | +$188K | ﹤0.01% | 2350 |
|
|
2017
Q4 | – | Sell |
-49,360
| Closed | -$971K | – | 2329 |
|
|
2017
Q3 | $971K | Buy |
+49,360
| New | +$759K | ﹤0.01% | 1844 |
|
Other funds holding AKBA
VCM
VPM
Prudential Financial's AKBA Position: Q1 2026 in Review
Prudential Financial reduced its Akebia Therapeutics (AKBA) stake by 22% in Q1 2026, selling an estimated $15.5K and leaving 40,274 shares worth $56K. The position accounts for ﹤0.01% of the portfolio, ranked #2300.
Prudential Financial first reported a position in AKBA in Q3 2017 and has held it in 28 quarters since. The position peaked at $3.12M in Q3 2021. 171 funds tracked by Wall St. Rank hold AKBA as of Q1 2026.
- Prudential Financial held 40,274 shares of Akebia Therapeutics worth $56K as of Q1 2026.
- Prudential Financial sold 11,250 Akebia Therapeutics shares in Q1 2026, an estimated $15.5K.
- Akebia Therapeutics made up ﹤0.01% of Prudential Financial's portfolio in Q1 2026, its #2300 holding.
- Prudential Financial first reported a position in Akebia Therapeutics in Q3 2017 and has held it in 28 quarters since.
- Prudential Financial's Akebia Therapeutics position peaked at $3.12M in Q3 2021.
- 171 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q1 2026.
Based on Prudential Financial's 13F filing for Q1 2026, filed 13 May 2026.